Sight Sciences Secures Landmark Court Victory Against Alcon: \$34 Million Damages and Ongoing Royalties Awarded

Summary of Key Developments

• U.S. District Court Preserves Jury’s Verdict: Alcon found to have willfully infringed three Sight Sciences patents related to the Hydrus® Microstent.
• Monetary Award: Sight Sciences awarded over \$34 million in damages for past infringement, including lost profits (\$5.5 million) and royalties (\$28.5 million).
• Ongoing Royalties: Alcon ordered to pay 10% of Hydrus revenue as ongoing royalties through November 10, 2028, when the last asserted patent expires.
• Final Judgment Pending: Supplemental damages and pre-judgment interest will be calculated once Alcon produces financial data. The judgment is subject to appeal and may also be impacted by USPTO reexamination proceedings.
• Legal Representation: Cooley LLP represented Sight Sciences; a \$5.4 million success fee will be recorded in operating expenses.

Detailed Analysis for Investors

Sight Sciences, Inc. (Nasdaq: SGHT), a leading eyecare technology company, announced a significant legal victory in its patent infringement case against Alcon and its Hydrus® Microstent business. The U.S. District Court for the District of Delaware issued an order on March 27, 2026, confirming the jury’s finding that Alcon had willfully infringed three Sight Sciences patents. This outcome preserves the jury’s verdict and awards Sight Sciences monetary damages exceeding \$34 million, plus ongoing royalties and supplemental damages.

Details of the Court Order

• The patents at issue are U.S. Patent Nos. 8,287,482; 9,370,443; and 11,389,328.
• The damages include:
  • \$5.5 million in lost profits for direct financial harm
  • \$28.5 million in royalties for Hydrus sales from launch through jury verdict
  • Additional supplemental damages and pre/post-judgment interest, amounts pending further financial data from Alcon
• Alcon must pay ongoing royalties at 10% of Hydrus revenue from the date of judgment until November 10, 2028.
• The judgment is subject to appeal and may be affected by ex parte reexamination proceedings initiated by Alcon at the USPTO.
• Cooley LLP, Sight Sciences’ legal counsel, will receive a \$5.4 million success fee, recorded in operating expenses and excluded from non-GAAP adjusted operating metrics.

Implications for Shareholders and Potential Price Sensitivity

• Financial Impact: The \$34 million award (plus pending supplemental damages and interest) is a significant cash infusion. The ongoing royalty arrangement ensures future recurring revenue tied to Hydrus sales until 2028.
• Intellectual Property Strength: The court’s recognition and enforcement of Sight Sciences’ patent portfolio underscores the company’s competitive moat in minimally invasive glaucoma surgery technologies.
• Potential Risks: The final judgment is not yet entered and remains subject to appeal. Alcon’s USPTO reexamination petitions could potentially affect the outcome.
• Accounting Note: The \$5.4 million success fee will impact reported operating expenses but will be excluded from non-GAAP adjusted figures.
• Strategic Impact: Sight Sciences’ leadership emphasized the critical importance of safeguarding their IP, which enables continued investment in new innovations for glaucoma care.
• Market Reaction: This legal victory and the prospect of ongoing royalties could materially affect SGHT’s share price, as investors assess both the near-term cash benefit and the long-term revenue stream.

Company Overview

Sight Sciences is an eyecare technology company developing innovative, interventional solutions for major eye diseases. Products include the OMNI® Surgical System (implant-free, minimally invasive glaucoma surgery), SION® Surgical System (bladeless device for excising trabecular meshwork), and TearCare® System (localized heat therapy for dry eye disease). Sight Sciences holds numerous trademarks and patents both in the U.S. and internationally.

Forward-Looking Statements

The company cautions that all forward-looking statements are subject to risks and uncertainties, including the timing and scope of the Court’s final judgment, ongoing royalty calculations, potential appeals, and impacts from USPTO proceedings. Actual results may differ materially from those expressed or implied.

Investor and Media Contacts

• Investor Relations: Philip Taylor, Gilmartin Group, 415.937.5406, [email protected]
• Media Contact: [email protected]

Disclaimer: This article is based on information disclosed by Sight Sciences, Inc. and may contain forward-looking statements. Investors should consult the company’s SEC filings and consider all risks before making investment decisions. This is not investment advice.

View Sight Sciences, Inc. Historical chart here